1)Fletcher CDM, Bridge JA, Hogendoorn PCW, et al : WHO Classification of Tumours of Soft Tissue and Bone. IARC, Lyon, pp10-11, 2013
2)Taylor BS, Barretina J, Maki RG, et al : Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 11:541-557,2011
3)Nishio J : Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors. Oncol Lett 5:12-18,2013
4)元井亨,加藤生真:軟部腫瘍の細胞遺伝学的診断法.病理と臨 30:127-135,2012
5)Gruver AM, Peerwani Z, Tubbs RR : Out of the darkness and into the light : bright field in situ hybridication for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 63:210-219,2010
6)Kiyose S, Igarashi H, Nagura K, et al : Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer : comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Pathol Int 62:728-734,2012
7)Motoi T, Kumagai A, Tsuji K, et al : Diagnostic utility of dual-color break-apart chromogenic in situ hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma. Hum Pathol 41:1397-1404,2010
8)Kumagai A, Motoi T, Tsuji K, et al : Detection of SYT and EWS gene rearrangements by dual-color break-apart CISH in liquid-based cytology samples of synovial sarcoma and Ewing sarcoma/primitive neuroectodermal tumor. Am J Clin Pathol 134:323-331,2010
9)熊谷有紗,元井亨,前川雅彦,他:Dual-color chromogenic in situ hybridization法の病理形態検査への応用と自動化のための基礎的研究.医学検査 61:366-373,2012
10)Ray-Coquard I, Blay JY, Italiano A, et al : Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma : an exploratory proof-of-mechanism study. Lancet Oncol 13:1133-1140,2012